NCT06511869

AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26)

A Phase II, Open-Label, Multicenter Study to Assess the Safety and Anti-Tumor Efficacy of AZD4205 in Participants With Peripheral T Cell Lymphoma Who Have Responded After First-Line Standard Therapy

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 48 (actual)
• Sponsor: Dizal Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is intended to assess the safety and anti-tumor activity of AZD4205 at 150 mg once daily in participants with PTCL who have achieved tumor response after first-line systemic therapy (with or without combination radiotherapy) and are ineligible for HSCT assessed by the investigator as ineligible for HSCT or have no plan for HSCT.

Conditions

• Peripheral T-cell Lymphoma

Interventions

Type	Name	Description
DRUG	AZD4205	AZD4205 capsules administered at 150 mg orally, once daily, in 28-day cycle.

Timeline

• Start date: 2022-03-17
• Primary completion: 2025-03-31
• Completion: 2025-03-31
• First posted: 2024-07-22
• Last updated: 2025-07-04

Locations

23 sites across 1 country: China